Claims for Patent: 8,703,177

Summary for Patent: 8,703,177

Title:	Abuse-resistant mucoadhesive devices for delivery of buprenorphine
Abstract:	The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphine is maximized.
Inventor(s):	Finn; Andrew (Raleigh, NC), Vasisht; Niraj (Cary, NC)
Assignee:	BioDelivery Sciences International, Inc. (Raleigh, NC)
Application Number:	13/590,094
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,703,177
Patent Claims:	1. An abuse deterrent mucoadhesive device for use in managing pain or opioid dependence, the device comprising: a mucoadhesive layer comprising between about 0.075 and about 12 mg of buprenorphine buffered to a pH of between about 4.0 and about 6.0; and a backing layer comprising between about 0.0125 and about 2 mg of naloxone buffered to a pH between about 4.0 and about 4.8, wherein the pH of the mucoadhesive layer and the pH of the backing layer are different, wherein the mucoadhesive layer and the backing layer comprise different combinations of polymers but each layer comprises at least one water-erodible polymer selected from the group consisting of: cellulosic polymers, olefinic polymers, polyethers and polyalcohols, and wherein following transmucosal administration excessive exposure to buprenorphine is avoided while the abuse-deterrent effect of naloxone is retained. 2. The device according to claim 1, wherein the w/w ratio of buprenorphine to naloxone present in the device is between 1:1 and 10:1. 3. The device according to claim 2, wherein the w/w ratio of buprenorphine to naloxone present in the device is 6:1. 4. The device according to claim 3, wherein the mucoadhesive layer is buffered to a pH of between about 4.50 and about 5.50 and the wherein the backing layer is buffered to a pH of between about 4.10 and about 4.4. 5. The device according to claim 4, wherein the mucoadhesive layer is buffered to a pH of about 4.75 and the backing layer is buffered to a pH of about 4.25. 6. The device according to claim 1 wherein the bioavailability of buprenorphine absorbed from the device is greater than 40%. 7. The device according to claim 1, wherein the at least one water-erodible polymer is selected from the group consisting of: polyacrylic acid (PAA), sodium carboxymethyl cellulose (NaCMC), hydroxypropylmethyl cellulose (HPMC), polyvinylpyrrolidone (PVP), hydroxyethylmethyl cellulose (HEMC), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), polyvinyl alcohol (PVA), polyethylene glycol (PEG), polyethylene oxide (PEO), and ethylene oxide-propylene oxide co-polymers.